Boehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical ...

The Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report ...

Bayer brings sevabertinib into the first-line setting in China — but Boehringer is already there: With the approval of ...

University of Oxford spinout Alethio Therapeutics has raised $90 million (about €80 million) to take its G6B-targeting ...

French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics' muscular dystrophy business.

As advanced therapies and vaccines reshape healthcare, Wacker ­Biotech is emerging as a CDMO partner of choice. With decades ...

Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics ...

The Basel region is one of the world’s leading life-science clusters. ­Pharmaceutical companies, biotech firms and research ...

Swedish biotech Alligator Bioscience has agreed to sell its CD40-targeting cancer immunotherapy mitazalimab to Canadian drug ...

Should a biotech hand its molecule to a single integrated partner, or build a network of specialists around it? Manufacturers and clinical providers are answering in both directions at once: some are ...

Denmark's Genmab said adding its bispecific antibody petosemtamab to MSD's Keytruda (pembrolizumab) cut the risk of death by ...

From Berlin biotech NOXXON through a strategic realignment and considerations of cryptocurrency investments, and now back to ...